Categories
Change Password!
Reset Password!
Rosuvastatin has long-lasting advantages in people
without cardiovascular (CV) diseases but are at risk of CV events..
Use of Rosuvastatin 10 mg was found to provide CV benefits
and lowers blood pressure (BP) in those with elevated systolic BP for at least
3 years even after its stoppage in people without CV disease representing a
legacy effect, outcomes of 8.7 years of an extended follow-up study of Heart
Outcomes Evaluation Prevention (HOPE)-3 trial portrayed.
In order to study if the CV events lowering benefits of
Rosuvastatin 10 mg daily is sustained or improved or attenuated even after its
cessation, the patients with elevated systolic
BP were called to participate in this 8.7 years ( 5.6 years plus 3.1 more years of observation).
The first co-primary outcome comprised of MACE-1 i.e. myocardial infarction,
stroke, or CV death. The second co-primary outcome comprised of MACE-2 i.e.
MACE-1 along with resuscitated cardiac arrest, heart failure, or coronary
revascularization.
Out of 11,994 surviving individuals of the HOPE-3 study,
9326 (78%) participated in this study. Compared with placebo, the individuals
initially randomized to rosuvastatin had a 20% and 17% additional reduction in
MACE-1 and MACE-2, respectively during a follow-up of 8.7 years. During the
active or after the trial observation period, no BP lowering benefit was
perceived, but MACE-1 was reduced by 24% in individuals with high systolic BP
over the total follow-up period.
European Heart Journal
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
Jackie Bosch et al.
Comments (3)